Sesen Bio, Inc. (SESN)
| Market Cap | 431.48M |
| Revenue (ttm) | 15.55M |
| Net Income (ttm) | -119.47M |
| Shares Out | 157.03M |
| EPS (ttm) | -0.92 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 12 |
| Last Price | $2.37 |
| Previous Close | $2.49 |
| Change ($) | -0.12 |
| Change (%) | -4.82% |
| Day's Open | 2.40 |
| Day's Range | 2.36 - 2.51 |
| Day's Volume | 3,804,398 |
| 52-Week Range | 0.62 - 3.57 |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported opera...
Hot penny stocks to watch this month. The post Penny Stocks To Watch For May 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported the g...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it w...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported opera...
Sesen Bio Submits Marketing Authorization Application to the European Medicines Agency for Vicineum™
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, announced that on Fr...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...
The FDA accepted the company's filing for approval of Vicineum in treating bladder cancer.
Hepion Pharmaceuticals (NASDAQ: HEPA) shares are trading lower Tuesday after the company priced its 44.2 million share common stock offering at $2 per share. Hepion Pharmaceuticals Inc is engaged in the...
Under priority review status, the FDA has accepted Sesen Bio Inc's (NASDAQ: SESN) marketing application for review seeking approval for Vicineum for the treatment of high-risk, BCG-unresponsive non-musc...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, announced today that...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...
Sesen Bio (SESN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported that ...
An analyst is very bullish about the biotech stock.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported that ...
Investors need to pay close attention to Sesen Bio (SESN) stock based on the movements in the options market lately.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced subm...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced favo...
Sesen Bio (SESN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, and Hikma Pharmaceut...
Sesen Bio, Inc. (SESN) CEO Thomas Cannell On Q3 2020 Results - Earnings Call Transcript
Sesen Bio, Inc.'s (SESN) CEO Thomas Cannell on Q3 2020 Results - Earnings Call Transcript
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported opera...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it w...
Sesen Bio (SESN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported opera...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--August 5, 2020 – Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, tod...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, and Qilu Pharmaceuti...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...
Sesen Bio, Inc. (SESN) CEO Dr.
Sesen Bio's (SESN) CEO Thomas Cannell on Q4 2019 Results - Earnings Call Transcript
Sesen Bio: Growing A Position Through The Rolling BLA Summary
Sesen Bio With High Probability FDA Approval Upcoming
Sesen Bio's (SESN) CEO Thomas Cannell on Q3 2019 Results - Earnings Call Transcript
ENZN trades at all time highs, adjusted for dividends, and double the "base case" of the liquidation value.
The company reported a positive data update from the Phase 3 VISTA trial for BCG refractory high-grade NMIBC patients.
Sesen plunged 35% after announcing a stock offering.
Investors need to pay close attention to Sesen Bio (SESN) stock based on the movements in the options market lately.
The stock more than doubled within the past two months.
Sesen Bio (SESN) needs investors to pay close attention to the stock based on moves in the options market lately.
The company meets with the FDA on May 20 to discuss manufacturing aspects.
About SESN
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule (EpCAM)... [Read more...]
| Industry Biotechnology | IPO Date Feb 6, 2014 |
| CEO Thomas Cannell | Employees 27 |
| Stock Exchange NASDAQ | Ticker Symbol SESN |
Analyst Forecasts
According to 3 analysts, the average rating for Sesen Bio stock is "Strong Buy." The 12-month stock price forecast is 7.00, which is an increase of 195.36% from the latest price.